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Summary
Carotid ultrasound allows rapid and reliable quantification
of atherosclerosis in humans. Although the definition of
carotid plaque is not uniform, intimal thickening of at least
1.5 mm is currently defined as plaque. Plaque can be eas-
ily quantified by tracing the plaque area, a software-in-
dependent low-cost technique. More sophisticated quan-
tifications involve 3D volume acquisitions, which is
software-dependent and not widely available. Carotid
plaque has a higher prognostic impact than intimal thick-
ening, and carotid plaque volume showed comparable
prognostic power to coronary calcifications. According to
the latest European Joint ESC guidelines, carotid artery
scanning should be considered for adjusting the level of
risk especially in intermediate-risk subjects. There are var-
ious methods to incorporate results from imaging into clin-
ical decision making, such as using arterial age instead
of chronological age in risk equations or post-test risk cal-
culations using the sensitivity and the specificity of the
results from a given carotid plaque burden. In subjects
with low or intermediate cardiovascular risk, the search
for atherosclerosis may be appropriate and ultrasound of
the carotid or the femoral arteries could be the primary
method applied (depending on local expertise). Assess-
ment of carotid total plaque presence, progression, stabili-
ty and regression over time may be a valuable clinical tool
for optimising the intensity of preventive therapies.
Keywords: atherosclerosis imaging, cardiovascular risk
prediction, coronary calcification, carotid intima-media
thickness, carotid total plaque area, carotid total plaque
volume, contrast enhanced carotid imaging
Introduction
Whenever illness or injury occurs, the question arises:
could it have been prevented?
The identification of factors that predict future risk in order
to manage and eventually reduce this risk are the subject
of extensive ongoing research. The INTERHEART study
showed that major independent cardiovascular risk factors
contribute to 90% of cardiovascular events [1]. According
to the Swiss Federal Statistical Office, cardiovascular and
cancer diseases remained the leading causes of mortality in
Switzerland in 2015. The National Health Accounts were
highest for cardiovascular disease (15.6%), which together
with cancer accounted for 22% of healthcare expenditure
in Switzerland [2].
Prevention of diseases associated with atherosclerosis is
therefore a primary healthcare issue. Traditionally, primary
care physicians assess atherosclerosis risk by examining
patients for the presence of traditional risk factors. The
modification of only seven risk factors (smoking, blood
pressure, cholesterol, obesity, sedentary lifestyle, malnutri-
tion, diabetes mellitus) has great potential to prevent pre-
mature all-cause morbidity and mortality in the population
[3, 4]. However, many patients reaching hospital with a
first ischaemic event are classified as low-risk subjects by
risk calculators [5, 6] such as PROCAM [7] or SCORE [8].
Direct visualisation of atherosclerosis may therefore be
warranted in order to reclassify subjects according to their
individual risk. Indeed, we have shown for two populations
from the Olten (Switzerland) and Koblenz (Germany) ar-
eas that the sensitivity of global risk calculators such as
PROCAM and SCORE is low for the detection of ad-
vanced carotid atherosclerosis assessed as the total carotid
plaque area [9] and the agreement between PROCAM and
SCORE with respect to risk category appears to be limited
[10]. The rationale for the addition of ultrasound to athero-
sclerosis management is the topic of this review.
Technical aspects of carotid ultrasound imag-
ing
Carotid ultrasound is performed with a linear array probe
(fig. 1) with a high frequency of at least 7 MHz in order
to obtain sufficient resolution to image small structures
[11]. The image resolution depends on the depth and the
frequency used [12, 13] and is usually around 0.3 mm
[14]. The anatomical region of interest is the tunica intima,
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which is assessed with 2D imaging without Doppler. Inti-
ma-media thickness (IMT) is the distance between the en-
dothelium and the tunica adventitia (fig. 2). According to
the Mannheim consensus, IMT is preferably measured in
the far wall segment of the last 10 mm of the common
carotid artery [15] (fig. 3). One major problem with carotid
IMT measurements lies in the diversity of methods used,
as described extensively elsewhere [16]. The variability of
carotid IMT measurements is lowest in the far wall of the
common carotid artery with the exclusion of carotid plaque
(figs 3 and 4), but this increase in reproducibility goes with
a loss in prediction of cardiovascular events [20, 21].
The sum of the longitudinal area of all plaques in the
carotid wall is termed total plaque area (TPA) and is mea-
sured from the clavicles to the jaws using multiple angles
to obtain the longitudinal circumference of all plaques in
the carotid tree, with inclusion of the proximal brachial
artery if possible [22] (fig. 4). Recently, carotid plaque
volume has been made available by use of the Philips iU
22 ultrasound system equipped with a single sweep vol-
umetric transducer (fig. 5), which covers 3.8 cm of the
carotid artery and visualises the distal part of the com-
mon carotid artery, the bulb and the proximal parts of the
internal carotid artery [23] (and personal communication
Philips AG, Zurich, Switzerland). Off-line software calcu-
lates the plaque areas from all obtained transversal images
in order to calculate the total plaque volume (TPV). Since
the field of view is only 3.8 cm, some plaques proximal
or distal to the transducer are missed and these plaques are
included in the total plaque area derived from longitudinal
carotid images (fig. 4). The advantage of the longitudinal
plaque imaging (TPA technique) is its high reproducibility
[24], vendor independence (no additional costs for surface
tracings) and the possibility to obtain the results without
additional software [14]. The definition of atherosclerot-
ic plaque versus non-atherosclerotic intimal thickening has
not been used uniformly in the literature (table 1). For clin-
ical purposes, an IMT increase of >1.5 mm or a focal thick-
ening of >50% when compared with adjacent structures is
the most commonly used approach [15].
Figure 1: A linear ultrasound probe.
Figure 2: Anatomy of the carotid artery wall. The image represents the far wall of the common carotid artery showing the intima and media,
defined by the distance between the endothelium and the external elastic membrane. For clinical purposes, the distance between the endothe-
lium and the tunica adventitia is measured to obtain the intima-media thickness (IMT).
Figure 3: Intima-media thickness (IMT measurement) according to the Mannheim consensus [15]. The carotid artery IMT should be par-
allel to the ultrasound beam and the measurement should be performed in the distal part of the common artery using a diastolic frame and ex-
cluding carotid plaque defined by (1) thickness >1.5 mm; (2) lumen encroaching >0.5 mm; (3, 4) >50% of the surrounding IMT value. The IMT
value should be derived from a length of 10 mm with 150 measures.
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Figure 4: Schematic view of the carotid artery, displaying fields of view and types of measurements. Principle measurements of athero-
sclerosis in the carotid artery are either intima media thickness (IMT; far wall of the distal part of the common carotid artery perpendicular to
the ultrasound beam in diastole according to the Mannheim Consensus [15, 17]); 3D plaque volume encompassing a field of view (FOV) of 3.8
cm using the Philips iU 22 ultrasound system [18], providing the a total plaque volume (TPV), which however may exclude plaque e.g. proxi-
mal or distal to the FOV of 3.8 cm; total plaque area (TPA), which measures all longitudinal plaque (in mm2) visible from the subclavian artery
to the most distal parts of the common and internal carotid arteries, usually over a FOV of 8.5 cm or more. The most information on the total
plaque burden is therefore provided by the TPA, followed by TPV and IMT. However, TPV can include plaques that are located laterally in the
vessel and not visible with the TPA method. Therefore, TPA should include also lateral plaque from transversal images. The correlation coeffi-
cient between TPA and TPV is r2 = 0.921 (p <0.0001) [19].
Figure 5: Semiautomatic measurements of transversal plaque areas obtained from a Philips iU 22 ultrasound system equipped with the single
sweep volumetric transducer vL 13-5. Analysis was performed offline with software provided by the manufacturer. The software calculates the
total plaque volume from all transversal carotid plaque areas obtained by the single sweep volumetric transducer over a field of view of 3.8 cm.
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Carotid atherosclerosis imaging with ultra-
sound and outcome
Outcome studies assessing the relationship between the
amount of carotid atherosclerosis and the incidence of is-
chaemic events in the heart and the brain are numerous.
Tables 2a–c summarise the largest ones, which included at
least 4000 subjects in cohort studies (table 2a). For com-
parison, outcome studies considering coronary calcifica-
tion are represented in table 2b and direct comparison stud-
ies in table 2c.
One of the first studies concerning the prognostic impact
on outcome of atherosclerosis imaging using carotid ultra-
sound was published in 1991 [55]. In 1288 Finnish men,
coronary event risk increased when compared with struc-
tural changes 2.2-fold for intimal thickening (p = NS), for
small carotid plaques 4.2-fold (p <0.01) and 6.7-fold for
stenotic plaque (p <0.01). In 1995, Japanese researchers
found carotid stenosis and plaque ulcerations to be pre-
dictive for ischaemic stroke [56]. In 1996, Belcaro et al.
found increases in plaque burden in carotid and femoral ar-
teries to be predictive for cardiovascular events and death
in 2322 asymptomatic subjects after a follow-up time of 6
years [57] and in 13,221 low-risk subjects (CAFES-CAVE
Study) after 10 years [38]. Spence showed in 2002 that
TPA was predictive for cardiovascular events with increas-
ing risk in the higher quartiles of TPA; the analysis in-
cluded 1686 patients, most of whom had had a previous
stroke or transient ischaemic attacks [28]. Of these, 684
were originally primary care patients, for whom it was
shown that the addition of posterior test probabilities based
on the Bayes theorem (table 3) improved discrimination
for predicting future myocardial infarction after 3.3 years
Table 1: Parameters frequently used for the quantification of carotid plaques.
Plaque characteristic Measurements Reference
Increase of IMT >1.0 mm Spence 1991 [25]
Doubling of IMT Spence 1991 [25]
Doubling of IMT Mannheim Consensus [15]
Thickening of IMT >1.2 mm Handa [26]
Subjective assessment Polak [27]
Encroaching into the lumen 0.5 mm Mannheim Consensus [15]
Increase of IMT ≥1.5 mm Mannheim Consensus [15],
Spence [28]
Texture changes Singh [29]
Plaque yes or no Nambi [30]
Subjective assessment Plaque burden none to severe Peters [31]
Plaque presence Number of plaques Plichart [32]
Plaque thickness In mm Rundek [33]
Plaque area In mm2 Spence [28]
Plaque volume In mm3 Baber [34]
Echo lucency Gray scale Stein [35]
Contrast agent Plaque vascularity Coli [36, 37]
IMT = intima-media thickness
Table 2: a: Major outcome studies using carotid intima media thickness and carotid plaque.
Author/acronym [ref.] n Outcome Effect
CAFES-CAVE [38] 10,000 Mortality No plaque: events 0.1%
Carotid plaque: events 3.0%
Rotterdam [39] 6389 AMI Plaque y/n: HR 1.6, 95% CI 1.2–2.2
Rosvall [40] 5163 AMI Plaque y/n: HR 1.8, 95% CI 1.5–2.9
IMT tertile 1/3: HR 1.5, 95% CI 0.8–2.6
Rosvall [41] 5163 Stroke Plaque y/n: HR 1.3, 95% CI 0.8–2.1
IMT tertile 1/3: HR 2.5, 95% CI 1.2–5.4
ARIC men [42] 5552 AMI IMT ≥1.0 mm: HR 1.9, 95% CI 1.3–2.7
ARIC women [42] 7685 AMI IMT ≥1.0 mm: HR 5.1, 95% CI 3.1–8.4
ARIC women [43] 7685 Stroke IMT <0.6/>1.0: HR 8.5, 95% CI 3.5–20.7
ARIC men [43] 6349 Stroke IMT <0.6/>1.0: HR 3.6, 95% CI 1.5–9.2
Tromsø [44] 6257 AMI TPA tertiles: HR 2.5, 95% CI 2.1–3.0
Tromsø men [35] 6226 AMI TPA tertiles: HR 1.6, 95% CI 1.04–2.4
Tromsø women [35] 6226 AMI TPA tertiles: HR 4.0, 95% CI 2.2–7.2
Tromsø men [35] 6226 AMI IMT quartiles: HR 1.7, 95% CI 0.98–3.1
Tromsø women [35] 6226 AMI IMT quartiles: HR 2.9, 95% CI 1.1–7.7
Tromsø men [45] 6844 Stroke TPA tertiles: HR 1.7, 95% CI 1.2–2.5
Tromsø women [45] 6844 Stroke TPA tertiles: HR 1.6, 95% CI 1.04–2.5
Tromsø men [45] 6844 Stroke IMT quartiles: HR 1.4, 95% CI 0.8–2.4
Tromsø women [45] 6844 Stroke IMT quartiles: HR 1.3, 95% CI 0.7–2.3
MESA [46] 6698 CVD IMT quartile HR: 1.7, 95% CI 1.2–2.5
MESA [47] 4955 CVD Carotid score: HR 1.2; 95% CI 1.2-1.4
AMI = acute myocardial infarction; ARIC = the Atherosclerosis Risk in Communities study; CI = confidence interval; CAFES-CAVE = carotid-femoral morphology and cardiovas-
cular events; CVD = cardiovascular disease; HR = hazard ratio; IMT = intima media thickness; MESA = the Multi-Ethnic Study of Atherosclerosis; TPA = total plaque area
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of follow-up (area under the curve [AUC] for NCEP III
risk 0.68, TPA-posterior test probability 0.75, p = 0.038)
[59]. In 2003, Hollander reported on 6913 prospectively
followed healthy subjects assessed in the Rotterdam study
and found that carotid IMT (with inclusion of regions with
carotid plaque) was a stronger predictor for ensuing stroke
than carotid plaque alone [60]. In 2004, Van der Meer re-
ported on 6389 subjects from the Rotterdam study with
assessments of carotid structural changes (carotid and
femoral plaque, carotid IMT with inclusion of plaque, aor-
tic plaque) and found equal predictive power for ensuing
myocardial infarction [39]. In 2007, Stein et al. reported
on 6226 originally healthy subjects assessed in the Norwe-
gian Tromsø study and found TPA to be a stronger, statisti-
cally significant marker for incident myocardial infarction
than IMT, especially in women, after correction for several
conventional cardiovascular risk factors [35] and this ob-
servation remained significant after an extended follow-up
of 15 years [44]. In a smaller study from China, Xie et al.
reported on 1734 subjects screened for ensuing myocardial
infarction and stroke, and found all measures of structural
changes in the carotid arteries (IMT measured at six sites,
TPA, number of plaques) to be effective for risk predic-
tion after adjustment for conventional cardiovascular risk
factors [61]. In 2010, Lorenz reported on the atheroscle-
rosis progression study including 4904 low-risk patients
with a follow-up of 10 years and found carotid IMT de-
rived from the common carotid artery, the bulb and the in-
ternal carotid artery to be less predictive than the Framing-
ham and SCORE risk models, but only 5% of subjects had
carotid plaques [62]. Again in 2010, Chambless published
the results from the Atherosclerosis Risk in Communities
study (ARIC), in which 13,145 subjects were followed
up for 15 years and assessed for traditional risk factors,
carotid IMT and presence of carotid plaque [30]. The AUC
increased significantly with the addition of carotid IMT or
carotid plaque to traditional risk factors. In 2011, Math-
iesen et al. reported on 6584 subjects assessed in the Trom-
sø study and found TPA but not common carotid IMT to
be predictive for incident ischaemic stroke after multivari-
ate adjustment [63]. In 2011, Polak reported that in 2965
members of the Framingham Offspring Study cohort eval-
uated for cardiovascular outcome during a follow-up of 7
years, both internal carotid IMT and internal carotid plaque
formation, defined as an IMT thickness of ≥1.5 mm, im-
proved the AUC significantly when compared with the
Framingham risk equation [64]. Naqvi gives an excellent
and comprehensive overview regarding outcome studies
performed with carotid ultrasound [20].
Several more recent reviews and meta-analyses have been
published in order to put different emerging imaging
modalities into perspective with the presence of structural
changes and outcome (table 2c). Simons analysed the
prognostic impact of carotid IMT compared with carotid
plaques using c-statistics (AUC) and found that carotid
IMT was not superior to the Framingham risk score for
the prediction of ischaemic heart disease [21]. In 2012
Den Ruijter et al. published a meta-analysis on 14 popu-
lation-based cohorts with data from 45,828 subjects and
compared common carotid IMT with the Framingham risk
score. They found a modest improvement in reclassifi-
cation and hazard ratio, but not for AUC [16]. Inaba et
al. published a meta-analysis of 11 population-based stud-
ies, which included 54,336 patients [54]. Compared with
carotid IMT, carotid plaque was a significantly better pre-
dictor of future myocardial infarction with AUCs of 0.61
and 0.64, respectively (p = 0.04).
Table 2b: Major outcome studies using coronary artery calcification.
Author/acronym [ref.] n Outcome AUC p-value
Raggi [48] 10,377 Mortality 0.72–0.78 0.001
Detrano [49] 6772 MACE 0.79–0.83 0.009
Arad [50] 4903 MACE 0.68–0.79 0.001
Erbel [51] 4129 MACE 0.65–0.76 0.001
MESA [52] 6814 MACE 0.75–0.80 0.001
MESA [46] 6698 CVD Quartile I vs IV: HR 4.4, 95% CI 2.8–6.8
MESA [47] 4955 CVD HR 1.78, 95% CI 1.16-1.98
MESA [53] 6814 CVD CAC 0: events 1.3–5.6%
CAC >300: events 13.1–25.6%
AUC = area under the curve; CAC = coronary artery calcium score; CI = confidence interval; CVD = cardiovascular disease; HR = hazard ratio; MACE = major adverse cardio-
vascular events; MESA = the Multi-Ethnic Study of Atherosclerosis
Table 2c: Meta-analyses on outcome studies comparing traditional risk factor models with carotid intima media thickness and carotid plaque.
Study [ref.] n Outcome Effect
Meta-analysis [16] 45,828 CVD Framingham AUC 0.76, 95% CI 0.75–0.76
Meta-analysis [16] 45,828 CVD Carotid IMT AUC 0.76, 95% CI 0.75–0.77
Comparison of AUC: statistically no significant improvement
Meta-analysis [54] 54,366 CVD Carotid plaque AUC 0.64, 95% CI 0.61–0.67
Meta-analysis [54] 54,366 CVD Carotid IMT AUC 0.61, 95% CI 0.59–0.64
Relative diagnostic odds ratio 1.4, 95%CI 1.1–1.8 ; p = 0.04
AUC = area under the curve; CI = confidence interval; CVD = cardiovascular disease; IMT = intima-media thickness
Table 3: Calculation of post-test risk using the Bayes theorem [58].
PTP positive: (PV × SE) / [PV × SE + (1 – PV) + (1 – SP)]
PTP negative: [PV × (1 – SE)] / [PV × (1 – SE) + SP × (1 – PV)]
PTP positive = post-test probability for a disease if the test is positive [pathological]; PTP negative = post-test probability for a disease if the test is negative [normal]; PV = pretest
probability [or prevalence {PV}] for a disease; SE = sensitivity; SP = specificity
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Direct comparison of carotid and calcified
coronary plaque for outcome prediction
Whereas initial outcome studies with atherosclerosis imag-
ing in the past compared one method with traditional risk
factors, two large-scale studies, BioImage [34] and MESA
[65], have directly compared coronary calcifications with
carotid ultrasound imaging (table 4). The BioImage study,
involving 5808 healthy subjects and published in 2015 by
Baber et al., directly compared the total volume of carotid
plaques acquired with a Philips iU 22 ultrasound system
(fig. 5). In a direct comparison of carotid TPV with the
presence and amount (score) of coronary calcium (a mea-
sure of the total calcified plaque burden in the whole coro-
nary tree), the predictive power for cardiovascular events
was noninferior in a low- to intermediate-risk population
(table 2b). The MESA study included 6779 healthy sub-
jects and was published by Gepner et al. in 2015 [65]. It
compared the presence of coronary calcium with the pres-
ence of carotid plaques and carotid IMT above the 75th
percentile to predict cardiovascular events and found that
only coronary calcium and carotid plaque presence were
predictive, whereas carotid IMT was not. For the predic-
tion of stroke / transient ischaemic attack, only the pres-
ence of carotid plaques was predictive after 9.5 years of
observation time.
Effect of medical intervention on carotid ath-
erosclerosis
In a meta-analysis of 41 randomised trials including
18,307 participants published in 2010, it was shown that
active treatment significantly reduced cardiovascular
events and all-cause death, but there was no significant
relationship between IMT reduction and cardiovascular
events [66]. This was later confirmed in a second meta-
analysis performed by Goldberger et al. [67]. It was not
confirmed in the IMPROVE-IT study, which included
3703 high risk patients (average Framingham risk score
22%): carotid IMT and its progression, but not carotid
plaque, led to significant improvements in risk reclassifi-
cation [68].
What to measure: carotid IMT, carotid plaque
or coronary calcium?
Regardless of traditional risk factors, structural arterial
changes revealed by atherosclerosis imaging are associated
with adverse cardiovascular outcomes. Although screening
with atherosclerosis imaging has not received a class I rec-
ommended indication in primary care, most cardiovascular
events occur in those not at high cardiovascular risk as cat-
egorised by traditional risk factors [5] and therefore, by in-
ference, additional testing might be helpful in further car-
diovascular risk stratification.
The inclusion of carotid plaque quantification into car-
diovascular risk prediction has significantly improved dis-
crimination and reclassification of subjects in primary care
[20, 21]. Carotid plaque is caused by atherosclerosis with
the presence of foam cells, smooth muscle cells, calcifi-
cations, macrophages, lipid cores and a fibrous cap [69].
However, the definition of plaque on ultrasound is not uni-
form (for details refer to table 1).
Several aspects might influence the choice of one test
rather than another. Expertise and availability are in-
evitable requirements, but cost, radiation burden, validity,
reproducibility, feasibility, test rapidity and the possibility
to track atherosclerosis in order to observe treatment ef-
fects are all also important. In our opinion, the use of
carotid TPA is probably the most suited for clinical prac-
tice, followed by a search for femoral bifurcation plaque
and aortic plaque, the use of the ankle-arm index or mea-
surement of plaque height with ultrasound in various vas-
cular beds.
More sophisticated tests are often time consuming and
costly or involve exposure to radiation, though it has re-
cently been shown that the latter can be reduced. The ac-
quisition of IMT is technically demanding, and requires an
ECG signal for images during diastole and a room tem-
perature of 22–25°C; plaque should not be excluded from
measurements in order to improve predictive accuracy for
cardiovascular events [17] (fig. 3).
Laclaustra reported a comparative study in which presence
(score >0) and extent (score >300) of coronary calcium
was taken as the golden standard and compared with the
ability of traditional risk factors, 3D carotid and 3D
femoral plaque volumes to correctly detect coronary cal-
cium within the same subject using AUC [70]. According
to this study, both carotid and femoral plaque were better
markers for the presence and extent of coronary calcifi-
cations than traditional risk factors and there was a ten-
dency toward a better performance of femoral over carotid
plaque, especially in smokers.
Cardiovascular risk increases with the carotid plaque bur-
den quantified as TPA. Spence performed a study with a
5-year observation time on the outcome of myocardial in-
farction, stroke or vascular-related death [28]: the unad-
Table 4: Direct comparison of coronary calcium scores with either carotid total plaque / carotid plaque volume or carotid intima media thickness in the BioImage [34] and MESA
[65] studies.
BioImage
n Age (years) Risk Fram. 10 y FU CVD* Modality CVD†
5808 68.9 9.20% 2.7 216 (4.2%) TRF 1.00
CCS 2.87 (1.73–4.74)
CPV 2.97 (1.92–4.60)
MESA
n Age (years) Risk 9.5 y FU CVD‡ Modality CVD Stroke/TIA AUC CVD AUC stroke
6779 62.2 7.90% 9.5 7.90% TRF 1.00 1.00 0.756 0.782
CCS 3.12 (2.44–3.99) 1.54 (1.09–2.18) 0.776 (p <0.001) 0.785 (p = NS)
CP§ 1.61 (1.17–2.21) 1.40 (1.35–1.45) 0.760 (p = 0.03) 0.787 (p = 0.045)
CIMT 75% 1.20 (0.94–1.52) 1.01 (0.70–1.47) 0.757 (p = NS) 0.783 (p = NS)
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justed risk was 13.5% and risk adjusted for various coro-
nary risk factors was 13.9% for the third quartile (TPA
range 46–118 mm2, average 78 ± 21 mm2). By linear ex-
trapolation, over a 10-year period a risk of 27.8% for my-
ocardial infarction, stroke or vascular-related death is ex-
pected. In a study by Xie et al. in China with a 4-year
follow-up, risk of stroke or myocardial infarction for the
third tertile of TPA (TPA above 30 mm2) was 10%, which
by linear extrapolation is 25% over 10 years. In the Tromsø
study with a 6-year outcome in over 6226 men and women,
with TPA >50 mm2 the event rate for the third tertile was
23% in 10 years (by extrapolation) in men and with TPA
>37 mm2 the event rate for the third tertile was 16% (by ex-
trapolation to 10 years) in women [35]. In a second Tromsø
study with a median observation time of 15 years, 894 my-
ocardial infarctions were observed. The TPA third tertile
was 80 ± 44 mm2 and was associated with a 10-year risk
of 24% [44]. Plaque growth occurs more in a longitudinal
than a transverse direction, so that measures of TPA cap-
ture changes in plaque growth more reliably than plaque
thickness or IMT [25].
Given the excellent predictive accuracy for cardiovascular
events of carotid TPV, which is indeed comparable to pres-
ence [65] and extent of coronary calcifications [34], it
might be argued that carotid TPV should be used instead
of carotid TPA. The correlation between carotid TPV and
TPA was tested by the core laboratory in Ontario, Canada,
which showed an extremely good correlation: r2 = 0.921 (p
<0.0001) [19]. TPA has been shown to change by about 10
mm2 per year, which makes it suitable for observing thera-
peutic effects over time [20, 71]. In order to avoid the prob-
lem of missed plaques situated in the lateral wall with TPA,
plaque area may be measured from transverse images (fig.
6).
Imaging recommendations and guidelines
The American College of Cardiology Foundation (ACCF)
/ American Heart Association (AHA) 2010 guidelines for
assessment of cardiovascular risk in asymptomatic adults
issued a class IIa recommendation for coronary calcium
assessment in subjects at intermediate risk, a IIa recom-
mendation for carotid IMT if carotid plaques are present, a
class IIb recommendation for coronary calcium in low-risk
subjects and a class III recommendation for ankle-brachial
index, pulse wave velocity and other measures of arterial
abnormalities such as arterial stiffness [72].
In 2013 the American College of Cardiology (ACC) /
AHA guidelines on cardiovascular risk assessment recom-
mended not using carotid IMT in clinical practice for car-
diovascular risk assessment, but carotid plaque retained a
Class IIa indication (“should be considered”) [73].
According to the latest Joint European Society of Cardiolo-
gy (ESC) guidelines, socioeconomic status, social isolation
or lack of social support, family history of premature car-
diovascular disease, elevated body mass index and central
obesity, computed tomography coronary calcium score,
atherosclerotic plaques determined by carotid artery scan-
ning and the ankle-brachial index should all be considered
as important factors for adjusting the level of risk [74]. In
this paper, carotid plaque but not carotid IMT was cate-
gorised as a very high-risk finding. The final recommen-
dation for coronary calcium scanning, ankle-brachial index
and carotid plaque imaging received a “may be consid-
ered” (class IIb) recommendation, whereas carotid IMT
Figure 6: Large carotid plaque in the carotid bulb, which contains plaque formation not visible in the longitudinal image.
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measurements are not recommended (class III indication)
in the latest Joint ESC guidelines [74].
According to US guidelines of 2018, coronary calcium
measurements may be indicated in intermediate risk pa-
tients (IIa recommendation), whereas carotid plaque was
not specifically addressed, except for the BioImage study
(carotid plaque volume) [34].
Assessment of global disease risk
In order to guide patients in their highly prevalent wish to
remain healthy until very old age, clinicians should utilise
appropriate tools to adequately predict risk for all-cause
morbidity and mortality. Unfortunately, such risk predic-
tion tools are not available. Whether the risk for all-cause
morbidity can be calculated by using the Framingham risk
equation for cardiovascular disease and a simple multipli-
cation factor if additional modifiable risk markers have to
be incorporated into such risk models should therefore be
a matter of investigation.
The first study on cardiovascular risk prediction associated
with only four modifiable risk factors (smoking, hyper-
tension, total cholesterol, high-density lipoprotein choles-
terol), derived from the Framingham cohort study, showed
clinically important results [75]. In the Cardiovascular
Lifetime Risk Pooling Project, the absence of smoking, hy-
pertension, elevated total cholesterol and diabetes resulted
in a life-time gain of 14 years free of any cardiovascular
disease [76]. Similarly, all-cause morbidity is significantly
influenced by these few risk factors, as was shown in the
Chicago Heart Association Detection Project in Industry
[3]: favourable cardiovascular health assessed at the age of
40 extended survival by 4 years and postponed the onset of
all-cause and cardiovascular morbidity by 4.5 and 7 years,
respectively, after an observation period of over 40 years.
Favourable risk factors at age 40 resulted in both lower cu-
mulative and annual healthcare costs later in life, support-
ing the idea of a reduction of costs as well as of morbidity.
Inclusion of 20-year trends in the Framingham Offspring
study showed that those who maintained ideal cardiovas-
cular health scores had significantly lower rates for cardio-
vascular diseases and all-cause mortality [4].
Many emerging risk factors have shown additional pre-
dictive power, especially regarding markers of inflamma-
tion [77], obesity [78] and atherosclerosis quantified via
imaging [79], as opposed to risk-reducing factors such as
healthful nutrition [23] and physical activity [80]. Impor-
tantly, a combination of favourable risk factors is associat-
ed with additional benefit, as was shown for the degree of
physical fitness and statin use versus no statin use [81] and
for the lack of subclinical atherosclerosis [4].
For clinicians, the predictive value of any test not included
in the cardiovascular risk charts has to be clearly sub-
stantiated in order to avoid unnecessary testing and ensu-
ing preventive activities. In Switzerland, the accuracy of
use of risk equations for predicting coronary or cardio-
vascular risk has not been prospectively tested, and ques-
tions regarding appropriate recalibration of PROCAM and
SCORE remain to be solved [82]. A cross-sectional ob-
servational study of patients admitted to hospital owing
to a first cardiovascular event, such as unstable angina or
acute myocardial infarction, unexpectedly suggested that
most of these patients were at low cardiovascular risk as
defined by SCORE or PROCAM [5]. In subjects aged 40
to 54 years, nearly 60% with low risk defined by coronary
risk charts had subclinical atherosclerosis [83] and nearly
50% of 1779 subjects without medication or convention-
al cardiovascular risk factors had subclinical atheroscle-
rosis, which was correlated only with age, male sex and
low-density lipoprotein cholesterol [84]. We have shown,
in a German and Swiss cross-sectional observation of 5104
healthy subjects, that the sensitivity of SCORE and PRO-
CAM is low in the detection of advanced carotid athero-
sclerosis (defined as a TPA >80 mm2) in the age group 40
to 65 years [9].
Therefore there is room for improvement in risk prediction.
Currently, the Swiss Heart Foundation uses the CARRIS-
MA calculator, which refines risk score results with inclu-
sion of physical activity, number of cigarettes smoked and
body mass index [85]. However, CARRISMA is not ex-
plicitly recommended by the Swiss National Atherosclero-
sis Prevention Guidelines (AGLA) and its additive value,
the improvement in conjunction with coronary risk predic-
tion tools such as SCORE and PROCAM, remains to be
verified. Other risk markers that should be used to assess
risk in a given patient are – according to AGLA – the pres-
ence of psychosocial stress factors, autoimmune-inflam-
matory diseases or atherosclerotic disease in arteries evi-
denced by imaging.
There are several reasons to implement additional tests in
primary prevention of cardiovascular disease in order to
improve the sensitivity and specificity of risk prediction.
Uncertainty about a true risk category, especially in low-
to intermediate-risk patients, may represent a trigger for
additional tests, since a substantial fraction of patients in
these risk categories have advanced atherosclerosis in sev-
eral vascular beds [83, 84] and in the carotid arteries [9].
However, the criteria for an additional screening test in pri-
mary care should fulfil several criteria (table 5).
Additional tests for improving patient manage-
ment
In view of the expansion of morbidity in populations with
increasing life expectancies, only an early optimisation of
risk factors is required for disease reduction [3, 4, 76, 86].
Therefore, the mission in primary care should be to reach
the well-defined goals of favourable risk factors in every
patient.
Despite numerous efforts of primary care physicians to
achieve such goals, the motivation of patients to achieve
them was rather poor in surveys of the control of cardio-
vascular risk factors in Switzerland [87]. Moreover, a for-
mal randomised trial designed to study the effect of ath-
Table 5: Criteria for additional screening test quality (adapted from
[58]).
1. Independent comparison with a gold standard
2. Large spectrum of pretest probabilities
3. Ability to change clinical decisions
4. High reproducibility
5. Validation in several populations
6. High accuracy to discriminate individuals with and without disease
discrimination
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erosclerosis imaging on smoking cessation rate showed
disappointing results [88] and a meta-analysis on this topic
had mixed results without showing significant effects of
such interventions [89]. Similarly, results from genetic
testing had no apparent effect on the motivation to improve
risk factors [90] at the patient level, for example with re-
spect to smoking abstinence rates or weight reduction in
the overweight. However, in diabetic patients, knowledge
of carotid atherosclerosis was helpful in improving cardio-
vascular risk management in an observational multicen-
tre study [91] and recently a large randomised prospective
study involving 3175 patients, showed that the patient’s
knowledge of their arterial age – derived from carotid ath-
erosclerosis – significantly improved adherence to lifestyle
modifications and medication [92].
The conclusion that additional testing does not help in risk
factor improvement is only true for the methods evaluat-
ed so far. The opposite was shown for the visualisation
of silent atherosclerosis [92]. Changing the emphasis from
negative aspects of cardiovascular risk factors to positive
and modifiable increases in healthy life years could be es-
sential in motivating patients and the currently healthy.
Since noncalcified atherosclerosis is reversible with inten-
sive risk factor modification, an expected reduction of ath-
erosclerosis with use of atherosclerosis tracking over time
may further increase the adherence of patients to preven-
tive therapies.
The reversibility of atherosclerosis with preventive inter-
ventions is a clinically relevant factor, as extensively
shown for lipid lowering drugs [71, 93–97], and the im-
proved prognosis with regression of coronary [98] and
carotid [28] atherosclerosis. Tracking carotid atherosclero-
sis over time using a test that incorporates TPA was shown
to reduce TPA in more than 10,000 intensively statin-treat-
ed patients by Spence in Canada [71], by Herder in Nor-
way [99] and by Sturlaugsdottir in Iceland [100]. Since
statins reduce cardiovascular risk and more intensive statin
use reduces TPA, carotid plaque regression or stabilisa-
tion should improve cardiovascular outcome. This is fur-
ther supported by Spence et al., who found that no pro-
gression or a reduction of carotid plaques over time was a
statistically significant predictor for fewer cardiovascular
events during follow up [28]. Therefore, TPA appears to be
a factor that is especially attractive for serial testing over
time in order to observe the effects of prevention on sub-
clinical atherosclerosis [71], and possibly to promote com-
pliance in patients and the still healthy.
Attempts to guide the intensity of preventive therapies by
using serial coronary calcium scores have yielded partial-
ly negative results [101]. The detection of a progression
of coronary calcium scores was found to have additional
prognostic power [102], but the changes in C-statistics and
reclassification were only modest [103]. Further, recent
scientific evidence found that – owing to healing processes
– statins increase the calcified plaque burden in coronary
arteries in terms of calcium density in the plaques but not
the calcified plaque volume [104]. In a meta-analysis using
TPV assessed with contrast-enhanced computed cardiac
tomography (including noncalcified coronary plaques),
high-intensity statin users had a significant decrease of
TPV by 21%, whereas TPV increased significantly by 15%
in non-statin users over a mean follow-up time of only
13 months [105]. A meta-analysis of intravascular coro-
nary ultrasound studies documented a decrease of coronary
plaque volume with an increase of calcified plaque volume
[106], which was verified in similar studies [107]. There-
fore, serial coronary calcium scores may not be clinically
useful when compared with serial TPA testing with respect
to cost and radiation burden, and should be avoided when
a baseline coronary calcium score is above 100. The new
US guidelines of 2018 state that in statin-treated patients
coronary calcium score follow-up examinations have “no
utility” [108].
For a clinician, a search for additional risk modifiers in pa-
tients with borderline findings is inconceivable. For exam-
ple, in a patient with a 9% risk for cardiovascular diseases
in 10 years, the presence of coronary or carotid athero-
sclerosis could trigger more intensive preventive care. Ac-
cording to the National Swiss Guidelines, target risk fac-
tors of the 10-year PROCAM risk adapted for Switzerland
are excessive values of single cardiovascular risk factors
(e.g., low density lipoprotein above 5.0 mmol/l), presence
of psychosocial risk factors (e.g., depression), autoimmune
inflammatory diseases or carotid plaque, but not carotid
IMT.
We addressed the cost efficiency of the addition of carotid
plaque imaging as a cardiovascular risk modifier and found
high cost efficiency when carotid ultrasound was added to
the clinical work-up in low-risk patients [109].
Personalised cardiovascular risk prediction
Assessment of cardiovascular or coronary heart disease us-
ing risk charts (e.g., SCORE) or risk equations (e.g., Fram-
ingham, PROCAM) is currently established. Cut-offs for
risk categories are arbitrary and range from low-to-inter-
mediate, to high and very high, and usually apply over a
time period of 10 years. When emerging risk factors are
found or quantified in clinical practice, the integration of
these findings to allow changes in risk categories is not
firmly established. According to the Joint ESC guidelines
on cardiovascular risk prediction, the simple presence of
a carotid plaque defines very high risk [74]. That this is
rarely the case can be seen from posterior calculations of
risk [110] (table 5): for example, using the sensitivity and
specificity of TPA in a man with 8.0% risk, a TPA of
51 mm2 would increase the risk (derived from the Trom-
sø study [35]) to 18.4 (95% confidence interval [CI]
12.5–26.2); in a women the risk would increase to 26.4
(95% CI 13.6–45.1). Therefore, the same amount of plaque
shifts a man to intermediate and a women to intermediate-
to-high coronary risk [111] (fig. 7).
Recently, the concept of “negative risk markers” was intro-
duced by Mortensen et al., who reported that the absence
of coronary artery calcification or the absence of carotid
plaque reduced the associated coronary risk defined by risk
charts by about 80% and 61%, respectively, in the BioIm-
age study [113].
Another possibility is to replace chronological age by ar-
terial age, in which the amount of the total carotid plaque
area defines a sex-specific arterial age that can be used in
the risk equation [112].
In clinical cardiology, carotid plaque imaging was de-
scribed as an additional measure of risk in 580 patients un-
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Figure 7: Clinical significance of plaque measurements by integration of the Bayes theorem. A plaque area of 23 mm2 (see fig. 6) cor-
responds to an arterial age of 34 years in men and 43 years in women. An arterial age of 70 years corresponds to a total plaque area (TPA) of
108 mm2 in men and 66 mm2 in women, with increased risk [112]. On the basis of data from the Tromsø study, an arterial age of 70 years cor-
responds to the 96th percentile in men (sensitivity 9%, specificity 97%) and to the 95th percentile in women (sensitivity 18%, specificity 95%).
According to the Bayes theorem, a person with a 4% risk and arterial age of 70 would then be reclassified to intermediate risk (men 11%,
women 13%). For a 10-year risk of 10%, an arterial age of 70 would increase the risk to 25% in men and 29% in women.
dergoing stress testing for suspected coronary artery dis-
ease, with independent and incremental prognostic power
with the addition of carotid plaque burden to the results of
exercise echocardiography [114]. Further, the presence of
obstructive coronary disease may be better predicted with
carotid plaque than with carotid IMT [115, 116] or with ex-
ercise testing [117]. Therefore, even in the work up of pa-
tients with suspected coronary artery disease, the knowl-
edge of the carotid plaque burden may improve prediction
of risk and presence of obstructive coronary artery disease.
A stratified analysis of cardiovascular outcome and base-
line coronary artery calcium scores in 13,644 patients as-
sessed between 2002 and 2009 showed that, after a follow-
up period of 9.4 years, use of a statin therapy was
associated with a reduction in major cardiovascular events
only in those with baseline coronary artery calcium score
>0 and the benefits from statin therapy correlated with the
severity of the score at baseline [118].
According to Nicolaides, the absence of carotid plaques
in low-risk patients confirms the low risk, but about 40%
have carotid plaques and should be treated as having in-
termediate or high risk [119]. In subjects at intermediate
risk without carotid plaque, a search for femoral plaques
in the bifurcation is the next preferred step, because of
the good correlation between femoral plaque with calcium
scores [70, 83, 119]. However, it has to be acknowledged
that the coronary calcium score maintains an excellent dis-
criminatory power to detect subjects at increased risk for
ischaemic heart disease [53]. As emphasised by Ahmadi
in an accompanying editorial, such powerful, yet simple,
imaging biomarkers should not be ignored in the era of
more individualised care [120].
In high-risk patients (based on traditional risk factors),
monitoring plaque progression or attenuation may be help-
ful in atherosclerosis management [119]. In general, se-
quential testing using carotid ultrasound first may be
preferable in clinical practice [110]. This approach was al-
so proposed by Ference et al., who found that progression
on regular follow-up with noninvasive imaging of ather-
osclerosis should modify the intensity of current preven-
tive therapies [121]. The incremental clinical and prognos-
tic information from contrast-enhanced carotid ultrasound
using microbubbles remains to be determined [36].
Conclusion
The number of years in full health increase substantially
only if all major and conditional cardiovascular risk factors
are under control. The allocation of more resources to in-
tensified primary prevention is likely to avoid an expan-
sion of disease and healthcare costs in an increasingly aged
population, if implemented early in life.
The identification of subjects at increased risk for car-
diovascular events using traditional risk factors is estab-
lished in clinical practice. However, about 40% of low-
risk subjects are classified as having low risk, despite the
presence of prognostically relevant atherosclerosis, and we
have shown recently that the addition of plaque informa-
tion to medical risk assessment is highly cost effective.
Carotid artery intimal thickening is a consequence of ath-
erosclerosis and an approximation of it is used as to detect
subjects with a high probability of future cardiovascular
events. This information has predictive power beyond tra-
ditional risk factors if global plaque burden (area or vol-
ume) is assessed as opposed to sampling small regions in
the carotid arteries (e.g., intima-media thickness). Whether
traditional risk factors should remain the preferred method
for cardiovascular risk assessment in subjects who are not
at high risk remains to be determined.
In subjects with low or intermediate cardiovascular risk,
the search for atherosclerosis may be appropriate and ultra-
sound of the carotid or the femoral arteries could be the pri-
mary method applied (depending on local expertise). Coro-
nary calcium scoring remains a well-established method to
accurately measure coronary and, to a lesser extent, cardio-
vascular risk and may be indicated in selected cases where
ultrasound does not yield conclusive results.
Assessment of carotid total plaque presence, progression,
stability and regression over time may be a valuable clini-
cal tool for optimising the intensity of preventive therapies,
and may improve adherence to a healthier lifestyle and pre-
ventive medication.
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